The Replimune Group, Inc. (NASDAQ: REPL) recently caught analysts’ attention as Jonathan Chang of Leerink Partners issued a “Market Perform” rating on April 13, 2026. This follow-up comes at a time ...

In a notable shift in investment sentiment, Replimune Group, Inc. (NASDAQ: REPL) received a “Hold” rating from Roger Song of Jefferies on April 13, 2026. With the stock currently priced at $4.76, the ...

On April 10, 2026, Veeva Systems Inc. (NYSE: VEEV) received a Neutral rating from Tyler Radke of Citigroup, suggesting a cautious outlook for the stock in light of its current trading dynamics.

On April 10, 2026, Madison Square Garden Sports Corp (MSGS) received a significant nod from David Joyce of Seaport Global, who initiated coverage with a “Buy” rating and a price target of $430. This ...

On April 9, 2026, Marvell Technology, Inc. (NASDAQ: MRVL) garnered an upgraded rating from Barclays analyst Thomas O’Malley, who shifted his stance to “Overweight” while setting a price target of $150 ...

East West Bancorp, Inc. (EWBC) has recently received a Buy rating from UBS, following an optimistic assessment from analyst Nicholas Holowko on April 7, 2026. This rating comes at a time when the ...

Marvell Technology, Inc. (ticker: MRVL), a key player in the semiconductor market, has recently caught the attention of investors as Barclays analyst Thomas O’Malley upgraded the company’s rating to ...

Alex Wright is an analyst from Jefferies specializing in the Consumer Cyclical sector. They are beginning to establish their track record, with 1 stock rating so far. Their current stats show a ...

Vital Farms, Inc. (VITL) has recently drawn attention with a Hold rating issued by Robert Moskow of TD Cowen o. Although the firm’s price target aligns with the current trading price of $12.77, this ...

On April 7, 2026, Western Alliance Bancorporation (WAL) was assigned a neutral rating by Nicholas Holowko of UBS, reflecting a cautious stance amid prevailing market dynamics. Despite its recent ...

First Horizon Corporation (FHN) received a Neutral rating from UBS analyst Nicholas Holowko, who set a price target of $25. This rating adjustment comes as investors seek clarity on the company’s ...

Apellis Pharmaceuticals, Inc. (APLS) received a Neutral rating from Douglas Tsao at HC Wainwright & Co., suggesting a cautious stance amid a turbulent market. At a current price of $40.39, this rating ...